PI3K/AKT/mTOR信号通路与乳腺癌多药耐药性研究进展  

Research Progress on PI3K/AKT/mTOR Signaling Pathway and Multidrug Resistance in Breast Cancer

作　　者：陈鸿艳 周宏宇 

机构地区：[1]昆明医科大学药学院暨云南省天然药物药理重点实验室,云南 昆明 [2]昆明医科大学现代生物医药产业学院,云南 昆明

出　　处：《生物医学》2025年第2期328-338,共11页Hans Journal of Biomedicine

基　　金：国家自然科学基金项目(82160697);云南省天然药物药理重点实验室开放基金项目(YKLPNP-K2503);云南省“兴滇英才支持计划”青年人才项目(YNWR-QNBJ-2018-380)。

摘　　要：乳腺癌多药耐药是导致乳腺癌治疗失败的主要原因。PI3K/AKT/mTOR信号通路异常激活与乳腺癌的发生发展及耐药性密切相关,抑制该通路是改善乳腺癌治疗效果和克服耐药的可行途径。目前,许多PI3K/AKT/mTOR信号通路抑制剂通过联合标准疗法克服乳腺癌的多药耐药正处于临床前或临床研究。本文综述了PI3K/AKT/mTOR通路在乳腺癌多药耐药中的作用以及通过抑制该通路克服乳腺癌多药耐药的策略研究。Multidrug resistance of breast cancer is the main cause of treatment failure of breast cancer. The abnormal activation of PI3K/AKT/mTOR signaling pathway is closely related to the occurrence, development and drug resistance of breast cancer. Inhibiting PI3K/AKT/mTOR signaling pathway is an effective way to improve the therapeutic effect of breast cancer and overcome drug resistance. At present, several PI3K/AKT/mTOR signaling pathway inhibitors are in preclinical or clinical research to overcome multidrug resistance of breast cancer. This article reviews the role of PI3K/AKT/mTOR pathway in breast cancer multidrug resistance and the research progress of strategies to overcome breast cancer multidrug resistance by inhibiting this pathway.

关 键 词：乳腺癌 PI3K/AKT/mTOR信号通路 多药耐药 抑制剂 

分 类 号：R737.9[医药卫生—肿瘤]